Averitas Pharma Announces FDA Approval of Qutenza for the Treatment of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy of the Feet
AACHEN, Germany and MORRISTOWN, N.J., July 21, 2020 /PRNewswire/ -- Grünenthal announced today that its U.S. subsidiary Averitas Pharma, Inc. received U.S. Food and Drug Administration (FDA) approval for Qutenza (capsaicin) 8% patch for the...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Brain | Diabetes | Drugs & Pharmacology | Endocrinology | Food and Drug Administration (FDA) | Germany Health | Neurology | Pain | Peripheral Neuropathy | Pharmaceuticals